Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2026 07:30 ET | Source: InflaRx N.V.

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
June 12, 2025 07:00 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel...
February 10, 2025 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure ...
July 19, 2024 09:01 ET | Source: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

Hamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic...
April 30, 2024 08:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.
February 27, 2024 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration ...
February 01, 2024 07:07 ET | Source: Panavance Therapeutics Inc.

Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)

Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal cells Misetionamide reduces energy...
January 29, 2024 07:03 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference

LOS ALTOS, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
November 21, 2023 07:07 ET | Source: Panavance Therapeutics Inc.

International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma

Misetionamide is effective in targeting and killing BRAF-mutated melanoma cells while preserving normal cellsBRAF-mutated melanoma accounts for approximately 50% of all melanomas BERWYN, PA, Nov. ...
September 12, 2023 07:07 ET | Source: Panavance Therapeutics Inc.

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer

Results showed antineoplastic activity in pancreatic tumor cell lines Metabolic and transcriptional findings demonstrate a molecular basis to reduce tumor cell proliferation and induce apoptotic cell...